Clinical Trial

A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 17, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a multicenter, open-label, phase 2 clinical study to evaluate the efficacy, safety and pharmacokinetics of YL202 in patients with locally advanced or metastatic breast cancer with TNBC, HR-positive, HER2-zero-expression or HER2-low-expression
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-05-27; most recent amendment 2026-07-16.
Status change: Active, Not Recruiting → Recruiting 2024-11-13
Status change: Not Yet Recruiting → Active, Not Recruiting 2024-06-19
Trial Details
NCT Number NCT06439771
Lead Sponsor MediLink Therapeutics (Suzhou) Co., Ltd.
Conditions Locally Advanced or Metastatic Breast Cancer
Enrollment 180 participants
Start Date 2024-04-23
Primary Completion 2026-07-30 (estimated)
Study Completion 2028-07-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-17